Abstract:Background The inflammatory biomarker YKL‐40 has previously been studied as a potential risk marker in cardiovascular disease. We aimed to assess the prognostic reclassification potential of serum YKL‐40 in patients with stable coronary artery disease. Methods and Results The main study population was the placebo group of the CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) trial. The primary outcome was a composite of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, and all‐cause mortality. We used Cox proportional hazards regression models adjusted for C‐reactive protein level and baseline cardiovascular risk factors. Improvement in prediction by adding serum YKL‐40 to the risk factors was calculated using the Cox‐Breslow method and c‐statistic. A total of 2200 patients were randomized to placebo, with a follow‐up duration of 10 years. YKL‐40 was associated with an increased risk of the composite outcome (hazard ratio per unit increase in (YKL‐40) 1.13, 95% CI 1.03–1.24, P =0.013) and all‐cause mortality (hazard ratio 1.32, 95% CI 1.17–1.49, P <0.0001). Considering whether a composite‐outcome event was more likely to have, or not have, occurred to date, we found 68.4% of such predictions to be correct when based on the standard predictors, and 68.5% when serum YKL‐40 was added as a predictor. Equivalent results were obtained with c‐statistics. Conclusions Higher serum YKL‐40 was independently associated with an increased risk of adverse cardiovascular outcomes and mortality. Addition of YKL‐40 did not improve risk prediction in patients with stable coronary artery disease. Clinical Trial Registration URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT00121550. Clinical Perspective What Is New? In patients with stable coronary artery disease, higher YKL‐40 is significantly related to cardiovascular events and mortality over 10 years of follow‐up after adjustment for standard predictors and high‐sensitivity C‐reactive protein, possibly reflecting high‐risk atherosclerotic progression and inflammation. What Are the Clinical Implications? In reclassification analysis YKL‐40 did not improve prognostic accuracy compared with predictions based only on standard predictors, and the value of measuring YKL‐40 to support clinical decision making appears limited. Introduction The desire to better assess prognosis in patients with cardiovascular disease (CVD) and further advance the understanding of the underlying atherosclerotic process has prompted the emergence of numerous potential CVD biomarkers. Many candidates have demonstrated consistent association with standard CVD outcome measures. Nonetheless, auxiliary predictive potential in addition to that offered by standard available clinical characteristics is in many cases absent or unclear, hindering translation of results into specific changes in patient management strategies. 1 , 2 , 3 However, in addition to possible utility in risk prediction, biomarker studies may unravel new key factors in CVD pathogenesis such as proinflammatory effectors, and ultimately help identify new potential upstream treatment targets. 4 , 5 YKL‐40, also known as chitinase‐3‐like‐1, is an inflammatory biomarker which has gathered increasing evidence during the past 2 decades. 6 It is considered an acute‐phase protein and has been specifically linked to the inflammatory process in the atherosclerotic plaque, 7 diseases of extracellular remodeling and fibrosis, 8 angiogenesis and regulation of proinflammatory cascades. 9 , 10 YKL‐40 has recently been associated with development of hyperlipidemia and ischemic stroke in a study of almost 10 -Abstract Truncated-

Serum YKL40: A novel potential link between inflammation and dyslipidemia in acne vulgaris

Evaluation of serum levels of interleukins 1‐beta, 10 and 12 in patients with acne vulgaris

Serum level of YKL-40, C-reactive protein and ESR in Patients with Vitiligo

Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations

Assessment of Serum Interleukin-36γ Level in Patients with Acne Vulgaris and Post -Acne Scars

Study of interleukin-1 beta expression in acne vulgaris and acne scars

Alterations in lipid and hormonal titers in patients with acne and their relationship with severity: A case‐control study

Increased YKL-40 Levels Are Linked with Disease Severity of Initially Diagnosed Graves’ Disease

YKL-40: a potential biomarker for osteoarthritis.

Evaluating the Role of Interleukin-36 and Interleukin-38 in Acne Vulgaris Patients

Serum zinc, selenium, and vitamin D levels in patients with acne vulgaris: A case-control study

Serum Uric Acid and Folic Acid Levels in Acne Vulgaris Patients

YKL-40 (chitinase-3-like protein 1) serum levels are associated with abdominal aortic calcification in hemodialysis patients

Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.

Evaluation of Interleukin-31 and C-reactive Protein in Inflammatory Acne Vulgaris Patients

Serum lipid profile in adolescents and adults with acne vulgaris receiving isotretinoin

The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review

The primary role of sebum in the pathophysiology of acne vulgaris and its therapeutic relevance in acne management.

YKL-40 Is Associated With Ultrasound-Determined Carotid Atherosclerotic Plaque Instability

Association between serum YKL-40 levels and endothelial function in hypertensive patients]

Correlation of serum Insulin-Like Growth Factor one with acne severity